These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 34403073)

  • 1. Development of In Vitro Endothelialised Stents - Review.
    Tsukada J; Mela P; Jinzaki M; Tsukada H; Schmitz-Rode T; Vogt F
    Stem Cell Rev Rep; 2022 Jan; 18(1):179-197. PubMed ID: 34403073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical investigation into the observation that silicon carbide coating on cobalt chromium stents leads to early differentiating functional endothelial layer, increased safety and DES-like recurrent stenosis rates: results of the PRO-Heal Registry (PRO-Kinetic enhancing rapid in-stent endothelialisation).
    Dahm JB; Willems T; Wolpers HG; Nordbeck H; Becker J; Ruppert J
    EuroIntervention; 2009 Jan; 4(4):502-8. PubMed ID: 19284073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent.
    Waksman R; Pakala R
    EuroIntervention; 2009 Dec; 5 Suppl F():F36-42. PubMed ID: 22100674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new rapamycin-abluminally coated chitosan/heparin stent system accelerates early re-endothelialisation and improves anti-coagulant properties in porcine coronary artery models.
    Gao JQ; Zheng JP; Jin HG; Zhang WQ; Yan PY; Chen T; Liu ZJ
    Clin Invest Med; 2014 Dec; 37(6):E395-402. PubMed ID: 25618272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk prediction of in-stent restenosis among patients with coronary drug-eluting stents: current clinical approaches and challenges.
    Sakamoto A; Sato Y; Kawakami R; Cornelissen A; Mori M; Kawai K; Fernandez R; Fuller D; Gadhoke N; Guo L; Romero ME; Kolodgie FD; Virmani R; Finn AV
    Expert Rev Cardiovasc Ther; 2021 Sep; 19(9):801-816. PubMed ID: 33470872
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhancement of endothelialisation of coronary stents by laser surface engineering.
    Li L; Mirhosseini N; Michael A; Liu Z; Wang T
    Lasers Surg Med; 2013 Nov; 45(9):608-16. PubMed ID: 24037969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are impaired endothelial progenitor cells involved in the processes of late in-stent thrombosis and re-endothelialization of drug-eluting stents?
    Zhao FH; Chen YD; Jin ZN; Lu SZ
    Med Hypotheses; 2008; 70(3):512-4. PubMed ID: 17764856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late stent thrombosis, endothelialisation and drug-eluting stents.
    Ertaş G; van Beusekom HM; van der Giessen WJ
    Neth Heart J; 2009 Apr; 17(4):177-80. PubMed ID: 19421365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.
    Alfonso F; Pérez-Vizcayno MJ; Cuesta J; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Cequier A; Velázquez M; Moreno R; Mainar V; Domínguez A; Moris C; Molina E; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández-Pérez C;
    JACC Cardiovasc Interv; 2018 May; 11(10):981-991. PubMed ID: 29798776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-generation drug-eluting stents versus drug-coated balloons for the treatment of coronary in-stent restenosis: A systematic review and meta-analysis.
    Kokkinidis DG; Prouse AF; Avner SJ; Lee JM; Waldo SW; Armstrong EJ
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):285-299. PubMed ID: 29024274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications.
    Lüscher TF; Steffel J; Eberli FR; Joner M; Nakazawa G; Tanner FC; Virmani R
    Circulation; 2007 Feb; 115(8):1051-8. PubMed ID: 17325255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late endothelial progenitor cell-capture stents with CD146 antibody and nanostructure reduce in-stent restenosis and thrombosis.
    Park KS; Kang SN; Kim DH; Kim HB; Im KS; Park W; Hong YJ; Han DK; Joung YK
    Acta Biomater; 2020 Jul; 111():91-101. PubMed ID: 32434081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5-7 years) follow-up of the Coronary Revascularization Demonstrating Outcome study-Kyoto registry Cohort-2.
    Natsuaki M; Morimoto T; Furukawa Y; Nakagawa Y; Kadota K; Yamaji K; Ando K; Shizuta S; Shiomi H; Tada T; Tazaki J; Kato Y; Hayano M; Abe M; Tamura T; Shirotani M; Miki S; Matsuda M; Takahashi M; Ishii K; Tanaka M; Aoyama T; Doi O; Hattori R; Kato M; Suwa S; Takizawa A; Takatsu Y; Shinoda E; Eizawa H; Takeda T; Lee JD; Inoko M; Ogawa H; Hamasaki S; Horie M; Nohara R; Kambara H; Fujiwara H; Mitsudo K; Nobuyoshi M; Kita T; Kimura T;
    Circ Cardiovasc Interv; 2014 Apr; 7(2):168-79. PubMed ID: 24550439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating endothelial progenitor cells are inversely correlated with in-stent restenosis in patients with non-ST-segment elevation acute coronary syndromes treated with EPC-capture stents (JACK-EPC trial).
    Wojakowski W; Pyrlik A; Król M; Buszman P; Ochała A; Milewski K; Smolka G; Kawecki D; Rudnik A; Pawłowski T; Jadczyk T; Wyderka R; Cybulski W; Dworowy S; Tendera M
    Minerva Cardioangiol; 2013 Jun; 61(3):301-11. PubMed ID: 23681133
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.